公开(公告)号：EP0420979A1

公开(公告)日：1991-04-10

申请号：EP89902067.1

申请日：1989-02-02

申请人： HANKYU-KYOEI BUSSAN CO., LTD.

发明人： KAGAWA, Kyoichi ,  KANEDA, Takaya ,  TADOKORO, Tetsuo ,  MATSUMURA, Yoshikazu, Ueda Chemical Ind.Co.Ltd.

IPC分类号： A61K37/18

CPC分类号： A23G1/56 ,  A23G3/346 ,  A23G2200/02 ,  A23J3/32 ,  A23J3/341 ,  A23J3/346 ,  A23K20/147 ,  A23K50/30 ,  A23V2002/00 ,  A61K38/011 ,  A61K38/012 ,  A23V2200/30 ,  A23V2250/55 ,  A23V2300/30

摘要： A lipid metabolism improving agent for human beings or animals and a method of its use are disclosed. Conventional lipid metabolism improving agents require a large amount of intake or unavoidably cause side effects on the human body and there have been no agents which are effective not only as lipid metabolism improving agents but also for depression of in increase of bodily fat accompanying growth acceleration of livestock animals and aquatic animals and improvement of accumulated fat. This agent contains as the active ingredient low-molecular peptides of 3 to 4 in average amino acid chain length produced by hydrolysis of a protein or a protein-containing substance. This agent is administered in an amount as small as 0.1 to 50% based on lipid intake, thus improving lipid metabolism effectively without side effects.

摘要翻译： 公开了一种用于人或动物的脂质代谢改善剂及其使用方法。 常规的脂质代谢改善剂需要大量的摄取或不可避免地对人体产生副作用，并且没有任何有效的药剂不仅可以作为脂质代谢改善剂而且对于伴随生长加速的身体脂肪增加的抑制也是有效的 的牲畜和水生动物，并增加积累的脂肪。 该试剂含有作为活性成分的蛋白质或含蛋白质物质的水解产生的平均氨基酸长度为3〜4的低分子肽。 该药物的施用量基于脂质摄取量少至0.1至50％，从而有效改善脂质代谢而无副作用。

公开(公告)号：EP0420979B1

公开(公告)日：1994-01-19

申请号：EP89902067.1

申请日：1989-02-02

申请人： HANKYU-KYOEI BUSSAN CO., LTD.

发明人： KAGAWA, Kyoichi ,  KANEDA, Takaya ,  TADOKORO, Tetsuo ,  MATSUMURA, Yoshikazu, Ueda Chemical Ind.Co.Ltd.

IPC分类号： A61K37/18

CPC分类号： A23G1/56 ,  A23G3/346 ,  A23G2200/02 ,  A23J3/32 ,  A23J3/341 ,  A23J3/346 ,  A23K20/147 ,  A23K50/30 ,  A23V2002/00 ,  A61K38/011 ,  A61K38/012 ,  A23V2200/30 ,  A23V2250/55 ,  A23V2300/30

摘要： A lipid metabolism improving agent for human beings or animals and a method of its use are disclosed. Conventional lipid metabolism improving agents require a large amount of intake or unavoidably cause side effects on the human body, and there have been no agents which are effective not only as lipid metabolism improving agents but also for depression of an increase of bodily fat accompanying growth acceleration of livestock animals and aquatic animals and improvement of accumulated fat. This agent contains as the active ingredient low-molecular peptides of 3 to 4 in average amino acid chain length produced by hydrolysis of a protein or a protein-containing substance. This agent is administered in an amount as small as 0.1 to 50% based on lipid intake, thus improving lipid metabolism effectively without side effects.